Classification of Patients with Mild Cognitive Impairment vs. Normal Controls based on Experimental and Conventional Standardized Measures of Processing.

Slides:



Advertisements
Similar presentations
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Advertisements

Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.
Department of Neurology, Mayo Clinic Arizona
Epidemiological study of mild cognitive impairment and pilot evaluation of methods of early dementia detection in Chinese community Yueqin Huang MD MPH.
Assessment/Enhancement of Cognitive Ability in Older Adults Karlene Ball Center for Research on Applied Gerontology University of Alabama at Birmingham.
ADNI 3 Clinical Core Plans
Significance of White Matter Hyperintensities in MCI Charles DeCarli University of California at Davis Alzheimer’s Disease Center Imaging of Dementia and.
Mary Ganguli’s Slides March 13 th Meeting. Mild Cognitive Impairment A View from the Trenches.
The New Brief Cognitive Assessment Tool (BCAT): The Role of Cognitive Assessment in Improving Health Outcomes Dr. William Mansbach October 25, 2011.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Mild Cognitive Impairment
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Risk of Developing Alzheimer’s Disease in Persons with MCI
Chair Timothy L. Vollmer, MD Professor of Neurology
Diffusion-Tensor Imaging Tractography: Correlation with Processing Speed in Aging Stephen Correia 1, Stephanie Y. Lee 2, Song Zhang 2, Stephen P. Salloway.
Mild Cognitive Impairment
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
1 A follow up study of mild cognitive impairment in Beijing ----finding from 10/66 study Zhaorui Liu, Chuanjun Zhuo, Yueqin Huang, Shuran Li, Institute.
Delusions, behavioural symptoms, quality of life and caregiver effects in AD Delusions, behavioural symptoms, quality of life and caregiver effects in.
ASNR 2015 Poster# EP-19 Effect of Chemotherapy on Brain Structure and Cognition in Older Women with Breast Cancer: a Brain MRI Study 1 Bihong T. Chen MD.
The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.
Shannon Denny, Annie Garner, MA, Crystal Franklin, MPH, Phillip Fine, MSPH, PhD, Despina Stavrinos, PhD UAB Translational Research for Injury Prevention.
Ramifications of Isotropic Sampling and Acquisition Orientation on DTI Analyses David H. Laidlaw 1, Song Zhang 1, Mark Bastin 2,3, Stephen Correia 4, Stephen.
EXECUTIVE DYSFUNCTION AS A RISK MARKER FOR SUBSTANCE ABUSE: THE ROLE OF IMPULSIVE PERSONALITY TRAITS Sara L. Dolan 1, Antoine Bechara 2, Peter E. Nathan.
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
Introduction The Coding subtests from the Wechsler scales are a commonly used portion of the Processing Speed Index. They are widely understood to measure.
The Influence of Feature Type, Feature Structure and Psycholinguistic Parameters on the Naming Performance of Semantic Dementia and Alzheimer’s Patients.
Diffusion-Tensor Imaging: Executive Function in Subcortical Ischemic Vascular Disease and Mild Cognitive Impairment Stephen Correia, Ph.D. Dementia Research.
CL Ropp 1, SL Tyas 1, KP Riley 2, KS SantaCruz 3 1 University of Waterloo, 2 University of Kentucky, 3 University of Minnesota March 29, 2011 The Impact.
 This research is part of a larger study entitled “Stress and Psychoneuroimmunological Factors in Renal Health and Disease” that is funded by The National.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
INTRODUCTION Previous literature suggests that schizophrenia is characterized by a disturbed, fragmented and/or poorly elaborated personal identity (e.g.,
Process Approach to Detecting Early Cognitive Impairment Rhoda Au, Ph.D., Friday Harbor 9/14/15 MBA.
Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.
METHOD METHOD Long-Term Neuropsychological Functioning Following Mild Traumatic Brain Injury Nathalie C. Bérard and Dennis P. Alfano CONCLUSIONS The group.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.
Identifying and Tracking Changes in Cognition Related to NPH Sheldon Herring, Ph.D. Clinical Director Outpatient Brain Injury and Young Stroke Program.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
NON PHARMACOLOGICAL THERAPY OF MENTAL IMAGERY AND RELAXATION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT Poptsi Ε.,1,3, Κounti F.,1,3,Τsolaki, Μ. 1,2 1.
Mild Cognitive Impairment, Activity Participation, Functional Difficulty, and Adaptations in Functionally Vulnerable Elderly People: A Closer Look Laraine.
The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.
Adeline SL Ng, Amanda RJ Ng, Ivane Chew, Nagaendran Kandiah Department of Neurology, National Neuroscience Institute, Singapore APOE4 status modulates.
The Clinical Utility of the LANSE- A and LANSE-C Jennifer L. Harrison, M.A., Megan Pollock, M.A., Amy Mouanoutoua, M.A. Ashley Brimager, M.A., & Paul C.
The Reliability and Validity of the Neurological Outcome Scale for Traumatic Brain Injury (NOS-TBI) in Persons with Post-Acute Traumatic Brain Injury (TBI)
A Novel Assessment Tool for Alzheimer's and Frontotemporal Dementias Jeanyung Chey 1,2, Hyun Song 2, Jungsuh Suk 1, & Minue J. Kim 3 The Proportional Reasoning.
Results Results Dillon C, MD, PhD; Vazquez G, MD, PhD ; Corrales A, MD; Allegri RF, MD, PhD; Taragano FE, MD, PhD. CEMIC University Hospital, SIREN, Department.
Association of Cognitive Outcomes and Response Status in Late Life Depression: A 12 Month Longitudinal Study David Bickford B.A., Alana Kivowitz B.A.,
Neuropsychological Aspects of assessing driving safety in the elderly
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Rachel L. Fazio, Psy. D. , Allison N. Faris, Psy. D. , Karim Z
C.Calia 1, L. Destino2, A. Semeraro 2, M. Pennelli 2, M. F. De Caro 2
Metabolic Syndrome and Progression of Mild Cognitive Impairment
Mobile Cognitive Training for Young Adults with Depressive Symptoms
Neurocognitive test battery
The BrainHealthRegistry
Table 1. Summary of Study Measures
Brief Computerized Measures of Information Processing Speed are Sensitive to Multiple Sclerosis across the Lifespan M. Shaw1, C. Schwarz1, L.B. Krupp1,
Joe Verghese, MBBS, MS. Translating Insights from
Mayo Clinic College of Medicine
Cognitive Biomarker of MS
FUNDING ACKNOWLEDGEMENT
by Edward J. Goetzl, Adam Boxer, Janice B. Schwartz, Erin L
Relationships Between the Questionnaire for Impulsive-Compulsive Disorders in Parkinson Disease-Rating Scale and Measures of Executive Function David.
چون آن مرغی که درهر برگ گل نقش خزان بیند
Boston Naming Test predicts deterioration of cerebrospinal fluid biomarkers in pre-symptomatic Alzheimer’s disease Charleen Wilder, MA, Kristina Moncrieffe,
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;
Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;
Presentation transcript:

Classification of Patients with Mild Cognitive Impairment vs. Normal Controls based on Experimental and Conventional Standardized Measures of Processing Speed and Working Memory. Erin Schlicting 1, Stephen Correia 2, Paul Malloy 2, Stephen Salloway 2 1 Department of Psychology, University of Rhode Island; 2 Department of Psychiatry and Human Behavior Brown Medical School & Butler Hospital, Providence, RI To determine if N-back and Self-Ordered Pointing Tasks (SOPT) improves classification of patients with amnestic mild cognitive impairment (MCI) vs. cognitively normal controls (NC) over and above standardized tests of processing speed and working memory. Acknowledgments: Support from: NIA ZAG1 FAS-5 (T32); Alzheimer’s Association NIRG ; NIMH K08MH01487W; The Human Brain Project (NIBIB & NIMH); Ittleson Fund at Brown; P20 NCRR ; Center for Translational Brain Research at Brown. Working memory (WM) and processing speed (PS) are often impaired in patients with amnestic MCI 1. Patients with MCI and deficits in WM and PS are at greater risk for conversion to dementia 2,3. Executive impairment (including WM and PS) adds to functional disability in Alzheimer’s disease 4,5. Experimental tests of WM and PS may improve discrimination between MCI and NC when combined with standardized WM and PS. Identifying patients at greatest risk for dementia is important for implementing early interventions. Background Objective Analysis Table 2: Cognitive Measures The results are consistent with prior findings of deficits in PS and WM in amnestic MCI 1,3. Performance on the SOPT and 3-Back tests improved discrimination of MCI from NC over and above standardized tests of PS and WM. WM performance is impaired in MCI and may help discriminating patients in the early stages of Alzheimer’s disease from controls 7. References 1.Nordlund, A. et al. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 76, (2005). 2.Albert, M.S., Moss, M.B., Tanzi, R. & Jones, K. Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 7, (2001). 3.Tabert, M.H. et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 63, (2006). 4.Boyle, P.A. et al. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 11, (2003). 5.Cahn-Weiner, D.A., Boyle, P.A. & Malloy, P.F. Tests of executive function predict instrumental activities of daily living in community-dwelling older individuals. Appl Neuropsychol 9, (2002). 6.Petersen, R.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, (1999). 7. Germano, C. & Kinsella, G.J. Working memory and learning in early Alzheimer's disease. Neuropsychology review 15, 1-10 (2005). MeasureProcessing SpeedWorking MemoryExecutive Function StandardizedSymbol DigitDigit SpanDRS IP Subtest Trails ASpatial SpanDRS AC Subtest Grooved PegboardLetter-Number Seq.Trails B Working Memory IndexCOWA Trails B-Trails A Experimental0-back Nback Task1, 2, & 3 Nback tasksN/A* (correct responses) 0, 1, 2, & 3 NbackSOPT Designs (reaction time)and Words *Experimental measures of executive function were not examined in this study Participants were 26 patients with amnestic MCI (Petersen criteria 6 ) and 20 age matched cognitive normal elderly controls (Table 1). All participants undertook a battery of cognitive tests including standardized and experimental measures of executive function, WM, and PS (Table 2). Participants Standardized Measures* Processing SpeedESWorking MemoryESExecutive FunctionES Symbol Digit0.48Letter-Number Sequencing0.11COWA0.07 Trails A0.21Digit Span - Total0.22Trails B - Trails A0.10 Grooved Pegboard Digit Span - Backward0.20Trails B0.21 Dominant0.17Spatial Span -Total0.17 Non-Dominant0.20Spatial Span - Backward0.28 Experimental Measures* Processing SpeedESWorking MemoryESExecutive FunctionES 0-Back Rxn Time0.14SOPT Abstract Designs0.37N/A 1-Back Rxn Time0.10SOPT Abstract Words Back Rxn Time0.091-Back Correct Responses Back Correct Responses Back Correct Responses0.40 *Effect sizes determined from values for partial η 2 : = Medium Effect; >.12 = Large Effect Table 3: Variables selected from the MANOVA The groups did not significantly by age or education (Table 1). No measures were excluded due to collinearity (all r <.65). MANOVA revealed a significant main effect for group (NC vs. MCI) p<.001. Measures from the MANOVA with medium effect sizes (ES, partial η 2 >.06 were selected for each DFA (Table 3). Each DFA produced one significant function: 1.Standardized measures (Wilks’ λ =.48; p<.001) 2.Experimental measures (Wilks’ λ =.40, p<.001) 3.Combined measures (Wilks’ λ =.28, p<.001) Table 4 lists the effect size for each DFA and the tests retained with corresponding effect sizes (1-Wilks’ λ). The combination of standardized and experimental tests of PS and WM was the strongest discriminator of MCI from NC. Table 1: Participant Characteristics NormalMild CognitiveSignificant ControlsImpairmentDifferences (n = 20; 55% Female)(n = 26; 42% Female) Variable MeanSDMeanSDp Value Age Education Correlations among cognitive variables within groups were examined to evaluate for possible collinearity. MANOVA procedure was used to identify significant differences between MCI’s and NC’s on standardized and experimental tests of WM and PS. Three DFA procedures were conducted, one using the standardized tests of WM, PS, and EF, a second using experimental test of WM and PS, and a third DFA combining measures retained from the two prior DFA’s. The effect sizes for the three DFA’s were examined to determine if combining standardized and experimental measures improved classification accuracy (MCI vs. NC). DFA ProcedureMeasures RetainedEffect Size* 1. Standardized Measures 0.52 Processing SpeedSymbol Digit0.71 Working MemorySpatial Span - Backward Experimental Measures 0.60 Processing SpeedNS Working MemorySOPT Abstract Designs Back Correct Responses Combined Measures 0.72 Processing SpeedSymbol Digit0.25 Working MemorySpatial Span - Backward0.15 SOPT Abstract Designs Back Correct Responses0.25 *Effect sizes for the DFA’s and measures retained in each discriminant function Table 4: Discriminant Function Analyses Conclusions Results